糖化血红蛋白对抗精神病药治疗时血糖的监测  

Evaluating the monitor role of glycohemoglobin in the treatment of antipsychotics

作　　者：傅伟忠[1] 瞿正万[1] 陈美娣[1] 古嘉琪[1] 王涛[1] 江琦[1] 王豪[1] 袁杰[1] 杨振东[1] 李亚明[1] 胡承平[1] 曹凤妹[1] 瞿嘉兴[1] 

机构地区：[1]上海市浦东新区精神卫生中心,200122

出　　处：《临床精神医学杂志》2007年第1期16-18,共3页Journal of Clinical Psychiatry

基　　金：上海市浦东新区社会发展局医学科研基金资助项目(PW2003-A3)

摘　　要：目的:探讨糖化血红蛋白(HbA1C)在抗精神病药治疗中对血糖变化的监测作用。方法:对198例单用氯丙嗪或利培酮治疗的精神分裂症住院患者于治疗前、治疗1、2、3、6、12个月测定HbA1C及血糖浓度并与常规血糖检测指标进行比较。结果:HbA1C浓度随治疗时间延长而增高,与血糖浓度变化呈显著正相关,与血葡萄糖调节受损(IGR)的发生呈平行发展,治疗1年后异常率为11.6%。结论:HbA1C检测稳定性好,结合空腹血糖等常规指标,是抗精神病药治疗中观察血糖变化的有效指标。Objective： To explore the monitor role of glycohemoglobin （HbAlc） in the treatment of antipsychotics. Method： 198 inpatients with schizophrenia were divided randomly into chlorpromazine group and risperidone group. HbAlc and fasting plasma glucose were tested before treatment and at 1,2,3,6,12 month after treatment, and compared with clinical routine fasting plasma glucose test. Results：The level of HbAlc trended to increase with the time of hospitalization and associated with the level of fasting plasma glucose and the incidence of imparied glucose regulation （IGR）, whose abnormality rate was 11.6 % one year after treatment. Conclusion： HbAlc can monitor IGR earlier, and is an efficacy index to the possible hyperglycemia in the treatment of antipsychotics when combined with routine fasting plasma glucose test.

关 键 词：糖化血红蛋白 抗精神病药 血糖 

分 类 号：R749.053[医药卫生—神经病学与精神病学]